Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Living Abroad: Social Inundation and Self-improvement - 2Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- 3Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- 4Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
- 5New science points to 4 distinct types of autism
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- Favored Vehicle for Seniors: Make Your Determination
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- Like 'accelerating from stationary to supersonic flight': Europe's Hera probe boosts speed, stays on course for November asteroid rendezvous
- Death toll from floods in Afghanistan rises to 61
- Polish law aimed at lowering petrol prices takes effect on Tuesday
- Which Film Has the Incomparable Melodic Score?
- Savvy Cleaning: The 6 Robot Vacuums of 2024
- Must-See Public Parks from Around the Globe
